Influence of Xinmailong Combined with Spironolactone on Patients with Chronic Pulmonary Heart Disease Complicated with Right Heart Failure
Objective:To observe the influence of Xinmailong combined with Spironolactone on cardiopulmonary function,hemorheology and 6 minutes walking test(6MWT)in patients with chronic pulmonary heart diseas complicated with right heart failure.Method:A total of 98 patients with chronic pulmonary heart disease and right heart failure in Department of Cardiology of People's Hospital of Gannan Tibetan Autonomous Prefecture from March 2020 to March 2023 were included in the study.All patients were randomly divided into observation group and control group,with 49 cases in each group.The patients in the control group were given routine treatment regimen,while the patients in the observation group adopted Xinmailong combined with Spironolactone on this basis.The clinical efficacy was compared between two groups,and the cardiopulmonary function[right ventricular end-diastolic diameter(RVEDD),stroke volume(SV),left ventricular ejection fraction(LVEF),forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC],hemorheological parameters[plasma viscosity,whole blood(low-shear,high-shear)viscosity,hematocrit]and 6MWT were recorded and compared before and after treatment between two groups.Result:The total clinical effective rates in observation group and control group were 91.84%and 75.51%respectively,and that in the observation group was significantly higher,the difference was statistically significant(P<0.05).After treatment,the levels of RVEDD in two groups were significantly declined than those before treatment,the differences were statistically significant(P<0.05),and that in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05);the SV,LVEF,FEV1,FEV1/FVC and 6MWT were significantly risen in both groups compared to those before treatment,the differences were statistically significant(P<0.05),and those in observation group were higher than those in control group,the differences were statistically significant(P<0.05);the levels of FVC in both groups were risen significantly,compared to those before treatment,the differences were statistically significant(P<0.05),there was no statistically significant difference between two groups(P>0.05);there were statistically significant differences in plasma viscosity in observation group,and whole blood low-shear viscosity,whole blood high-shear viscosity and hematocrit in both groups compared with those before treatment(P<0.05),and those in the observation group were significantly lower than those in control group,the differences were statistically significant(P<0.05).Conclusion:Xinmailong combined with Spironolactone can effectively enhance the therapeutic effect,improve the cardiopulmonary function,reduce the blood viscosity,and enhance the physical strength in the treatment of patients with chronic pulmonary heart disease complicated with right heart failure.
万方数据
维普
